Mirtazapin !@ctavis (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes serotonin 5‑HT2 and 5‑HT3 receptors. This dual action enhances overall serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirtazapin !@ctavis is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when appropriate.

To request Mirtazapin !@ctavis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its receptor profile. It often causes sedation and weight gain, which can be advantageous for patients with insomnia or low appetite, whereas SSRIs may have a lower risk of these effects but can cause sexual dysfunction.

Mirtazapin !@ctavis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Mirtazapin !@ctavis is taken orally, usually once daily in the evening, as directed by a healthcare professional. It can be swallowed whole with water; tablets should not be crushed or chewed unless specifically instructed.

Serious risks include the potential for agranulocytosis, severe hypersensitivity reactions, and the emergence or worsening of suicidal thoughts, especially during the early weeks of therapy. Patients should be monitored closely for any signs of these conditions.

Mirtazapin !@ctavis is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment without appropriate dose adjustment.